default author photo

Kan Yonemori

National Cancer Center Hospital - Department of Breast and Medical Oncology

Tokyo

Japan

SCHOLARLY PAPERS

3

DOWNLOADS

373

TOTAL CITATIONS

0

Scholarly Papers (3)

1.

CYP2D6 Genotype-Guided Tamoxifen Dosing in Hormone Receptor-Positive Metastatic Breast Cancer (TARGET-1): A Randomized, Open-Label, Phase 2 Study

Number of pages: 35 Posted: 06 Apr 2019
National Cancer Center Hospital - Department of Breast and Medical Oncology, Keio University - Department of Clinical Pharmacokinetics and Pharmacodynamics, Toranomon Hospital - Department of Medical Oncology, Fukushima Medical University, Yokohama City University, National Cancer Center Hospital - Department of Breast and Medical Oncology, National Hospital Organization Hokkaido Cancer Center - Department of Breast Surgery, Showa University - Advanced Cancer Translational Research Institute, Kumamoto Shinto General Hospital, Tokyo-West Tokushukai Hospital, Seirei Sakura Citizen Hospital, University of Texas at Houston - MD Anderson Cancer Center, RIKEN Center for Integrative Medical Sciences, RIKEN Center for Integrative Medical Sciences, National Cancer Center Hospital - Department of Breast and Medical Oncology and Keio University - Department of Clinical Pharmacokinetics and Pharmacodynamics
Downloads 147 (502,974)

Abstract:

Loading...

breast cancer, CYP2D6, endoxifen, genotype-guided dosing, tamoxifen

2.

Impact of Germline Variants on Breast and Ovarian Cancer Risk in Japanese Women: An Original Cohort Study and Meta-Analysis

Number of pages: 41 Posted: 04 Nov 2024
National Cancer Center Research Institute, University of Shizuoka, National Cancer Center Research Institute, RIKEN Center for Integrative Medical Sciences, National Cancer Center Hospital, National Cancer Center Hospital, National Cancer Center Hospital, National Cancer Center Hospital, Kanagawa Cancer Center, Saitama Medical University, University of Tokyo, Graduate School of Frontier Sciences, Department of Computational Biology and Medical Sciences, National Center for Global Health and Medicine, National Cancer Center Hospital, Kanagawa Cancer Center, Fukushima Medical University, Yamanashi Prefecture Central Hospital, Fukushima Medical University, Yamanashi Prefecture Central Hospital, Jikei University - School of Medicine, Showa University, National Cancer Center Hospital, National Cancer Center Hospital, National Cancer Center Hospital, National Cancer Center Hospital, National Cancer Center Hospital, National Cancer Center Hospital, National Center for Global Health and Medicine, National Center for Global Health and Medicine, National Cancer Center Hospital, National Cancer Center Hospital, Japanese Foundation for Cancer Research, Kanagawa Cancer Center, Kanagawa Cancer Center, Kanagawa Cancer Center, Yokohama City University - Department of Obstetrics and Gynecology, RIKEN Center for Integrative Medical Sciences, RIKEN Center for Integrative Medical Sciences, RIKEN Center for Integrative Medical Sciences, Saitama Medical University, Fukushima Medical University, Fukushima Regional Center for the Japan Environmental and Children’s Study, Yamanashi Prefecture Central Hospital, Showa University, National Cancer Center Research Institute, National Cancer Center Research Institute, National Cancer Center Hospital, National Cancer Center Hospital, Tokyo Medical and Dental University, National Cancer Center Research Institute, National Cancer Center Research Institute, National Cancer Center Research Institute, National Cancer Center Hospital, National Center for Global Health and Medicine - National Center Biobank Network, National Center for Global Health and Medicine - Genome Medical Science Project, National Center for Global Health and Medicine - National Center Biobank Network, Independent, Showa University - Department of Obstetrics and Gynecology, Jikei University - School of Medicine, Yamanashi Prefectural Central Hospital - Genome Analysis Center, Fukushima Medical University - School of Medicine, Kanagawa Cancer Center, University of Tokyo, National Center for Global Health and Medicine - Genome Medical Science Project, Saitama Medical University, National Cancer Center Hospital, National Cancer Center Hospital, Kanagawa Cancer Center, National Cancer Center Hospital, National Cancer Center Hospital, National Cancer Center Hospital - Department of Breast and Medical Oncology, National Cancer Center Research Institute and National Cancer Center Research Institute
Downloads 125 (576,708)

Abstract:

Loading...

breast cancer, ovarian cancer, Cancer predisposition genes, Cumulative cancer risk

3.

Avelumab Alone or in Combination with Chemotherapy vs Chemotherapy Alone in Platinum-Resistant or Platinum-Refractory Ovarian Cancer (JAVELIN Ovarian 200): A Randomised, Open-Label, Phase 3 Study

Number of pages: 52 Posted: 28 Oct 2020
ARCAGY-GINECO, Saitama Medical University International Medical Center (SIMC), University College London - UCL Cancer Institute, University of Toronto - Princess Margaret Cancer Centre, University College London - UCL Cancer Institute, University of Claude Bernard Lyon 1 - Medical Oncology Department, Cabrini Hospital - Department of Medical Oncology, Ospedale San Giovanni - Oncology Institute of Southern Switzerland (IOSI), National Cancer Center Hospital - Department of Breast and Medical Oncology, Government of the United Kingdom - Royal Marsden NHS Foundation Trust, Université Paris XI Sud - Gustave Roussy Cancer Campus, BC Cancer, University of Ulsan - Department of Oncology, Poznan University of Medical Sciences - Department of Oncology, National Cancer Center - Center for Uterine CancerNational Cancer Center, Korea - Center for Gynecologic Cancer, Willamette Valley Cancer Institute and Research Center, Pfizer Oncology, Pfizer Oncology, Pfizer, Inc. - Pfizer Global Biometrics and Data Management, Pfizer Oncology and University of Arizona - College of Medicine, Arizona Oncology (US Oncology Network)
Downloads 101 (684,672)

Abstract:

Loading...

ovarian cancer, Avelumab, PD-L1, Phase 3, immune checkpoint inhibitor